Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc shows a promising growth trajectory in its Precision Diagnostics and Radiopharmaceutical Oncology sectors, highlighted by the anticipated increase in market share for the POSLUMA PSMA PET imaging product, which is expected to achieve high single-digit revenue and unit share growth by the first quarter of 2025. The introduction of an enhanced Pylarify formulary—boosting batch sizes by approximately 50%—is projected to reinvigorate growth starting in the fourth quarter of 2026, supported by three years of TPT eligibility. Furthermore, the potential for significant contributions from non-Pylarify segments may exceed current growth and margin models, thereby enhancing the company’s earnings per share expectations for 2026 and 2027.

Bears say

Lantheus Holdings Inc. has reported a decline in Pylarify revenue, amounting to $260 million, which represents an 8% year-over-year decrease and fell approximately $14 million short of consensus estimates, indicating weaker demand than anticipated. Additionally, the company's unit growth was considerably lower than expected, recording only a 2% increase year-over-year amid a significant 10% price headwind. The downward revision of Pylarify growth forecasts for 2025-2026, combined with Lantheus’s overall growth profile trailing behind profitable SMID MedTech peers, further underscores the challenges the company faces in maintaining market competitiveness.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.